Pharmaceutical - Financial, Oncology

Filter

Current filters:

FinancialOncology

Popular Filters

1 to 25 of 81 results

Bleaker future for men with prostate cancer in England

04-02-2015

Today marks World Cancer Day, which this year focuses on “achieving treatment for all.” However,…

FinancialHealthcareJevtanaOncologyPharmaceuticalSanofiUK

GSK and Novartis get European clearance for asset swap

GSK and Novartis get European clearance for asset swap

29-01-2015

UK pharma major GlaxoSmithKline has received clearance from the European Commission for its proposed…

EuropeFinancialGlaxoSmithKlineNovartisOncologyPharmaceuticalUK

NHS England raises budget for Cancer Drugs Fund but axes some products

NHS England raises budget for Cancer Drugs Fund but axes some products

13-01-2015

As has been widely expected and already much criticized, England’s over-stretched Cancer Drugs Fund…

FinancialHealthcareOncologyPharmaceuticalUK

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Roche drops rights to Inovio’s prostate cancer candidate

17-11-2014

Swiss pharma major Roche has terminated its 2013 collaboration, option, and license agreement with US…

Anti-viralsFinancialINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Dendreon seeks a buyer as it files for bankruptcy

Dendreon seeks a buyer as it files for bankruptcy

10-11-2014

US biotech firm Dendreon has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the…

DendreonFinancialOncologyPharmaceuticalProvengeUSA

Merck & Co third-qtr disappoints, as earnings plunge

Merck & Co third-qtr disappoints, as earnings plunge

27-10-2014

US pharma giant Merck & Co (NYSE: MRK) posted third-quarter 2014 financial results today, showing that…

FinancialKeytrudaMerck & CoOncologyPharmaceuticalRegulationUSA

Merck Serono on track with pharma strategy

Merck Serono on track with pharma strategy

18-09-2014

Germany’s Merck KGaA says that its biopharmaceutical division - Merck Serono - is well on track with…

ataciceptBiosimilarsFinancialGermanyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearchTH-302

AACR report calls for US cancer funding to be a national priority

AACR report calls for US cancer funding to be a national priority

18-09-2014

Declining budgets have slowed the pace of research into cancer, according to a new report from the American…

AbraxaneCyramzaFinancialGazyvaImbruvicaNexavarOncologyPharmaceuticalResearchTafinlarUSAZydelig

Edison re-evaluates Onconova based on extended rigosertib timeline after trial failure

Edison re-evaluates Onconova based on extended rigosertib timeline after trial failure

29-08-2014

After failing to meet the primary endpoint of its trial of rigosertib (IV), oncology specialist Onconova…

FinancialMyelodysplastic syndromeOncologyOncology specialistOnconova TherapeuticsPharmaceuticalrigosertibUSA

Recipharm inks deal with Isofol Medical on Modufolin

Recipharm inks deal with Isofol Medical on Modufolin

26-08-2014

Swedish contract development and manufacturing group Recipharm and Isofol Medical AB, a Gothenburg-based…

FinancialIsofol MedicalModufolinOncologyPharmaceuticalProductionRecipharmResearch

Vernalis achieves research milestones in Servier oncology collaborations

Vernalis achieves research milestones in Servier oncology collaborations

04-08-2014

UK biopharmaceutical company Vernalis and Servier, France’s largest independent drugmaker, say that…

FinanceFinancialFranceIan GarlandOncologyPharmaceuticalResearchServierUKVernalis

Currency takes toll on Roche first-half results

Currency takes toll on Roche first-half results

24-07-2014

Swiss pharma major Roche, the world’s leading oncology company, this morning posted first-half 2014…

FinancialOncologyPharmaceuticalRocheSwitzerland

Bayer milestone for Compugen in cancer immunotherapy deal

Bayer milestone for Compugen in cancer immunotherapy deal

07-07-2014

Shares of Israel-based Compugen rose nearly 4% in pre-market trading today, after it said it has achieved…

BayerCompugenFinancialOncologyPharmaceuticalResearch

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials

03-05-2014

US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

Merck Serono’s Erbitux to be funded by CDF in England for mCRC

28-02-2014

The UK’s Cancer Drugs Fund (CDF) says that Erbitux (cetuximab) can be used in the first line setting…

ErbituxFinancialHealthcareMerck KGaAMerck SeronoNorthern EuropeOncologyPharmaceuticalUK

Australian patients benefit from PBS changes; cancer research

27-02-2014

New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing…

Asia-PacificAustraliaDiabetesFinancialHealthcareKombiglyzeOncologyPharmaceuticalResearchTrajentaVotrient

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

26-02-2014

US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

Mologen raises cash to fund Phase III trial of colorectal cancer drug

19-02-2014

German drug development company Mologen has raised 15.7 million euros ($21.6 million) in order to fund…

FinancialGermanyOncologyPharmaceuticalResearch

Topotargetin receives $17.8 million in milestone payments and could receive another $25 million

10-02-2014

Danish oncology drug development company Topotargetin (OMX: TOPO) has been the subject of an increased…

belinostatDenmarkFinancialOncologyPharmaceuticalTopotarget

1 to 25 of 81 results

COMPANY SPOTLIGHT

Menarini

Back to top